Breaking News
DetectaChem/MD-Bio Introduce Assay for Monkeypox Detection
DetectaChem and its subsidiary MD-Bio, the global leaders in innovative threat detection solutions used extensively by the U.S. Department of Defense, U.S. Homeland Security, law enforcement, first responders and public health agencies around the world, today announce the launch of their MD-Bio qPCR Monkeypox Detection Assay.
As the global need for monkeypox testing solutions rapidly grows, the MD-Bio qPCR Monkeypox Detection Assay will give testing centers the ability to quickly and accurately screen for active monkeypox infections using their own PCR machines.
The MD-Bio qPCR Monkeypox Detection Assay works by detecting active infections through targeting the hemagglutinin gene found in the virus.
“In the U.S. and around the world, we are seeing cases sharply rising and in response we have worked to launch a viable testing assay solution,” says DetectaChem and MD-Bio COO, Travis Kisner. “This new assay will help our testing centers and communities prepare for any surges in monkeypox cases or testing needs.”
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more
Almirall Appoints Mercedes Diz as VP, Corporate Strategy
Almirall, a global biopharmaceutical company focused on skin health, today announced that Mercedes Diz will […]
Viome Life Sciences Unveils CancerDetect™, the Future of Oral and Throat Cancer Detection
Viome Life Sciences, a mission-driven biotechnology company, announces the arrival of its CancerDetect™ test for oral […]
New Two-year Data Confirm Roche’s Vabysmo Improves Vision With Fewer Treatments for People With Neovascular Age-related Macular Degeneration
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the TENAYA and […]
Remington Announces Launch of VascuChek®, A Wireless, Vascular Doppler Device
Remington Medical, a medical device manufacturing company based in the U.S., announced the launch of […]
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) […]
Theolytics Starts a £1m Project in Collaboration With the University of Sheffield, Supported by Innovate UK to Develop a Novel Therapy for Multiple Myeloma Patients
Theolytics is a biotechnology company harnessing viruses to combat disease. The company has been awarded […]
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, have announced the […]
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, […]
DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and myeloid […]
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today […]
Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic
Vyriad announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the […]
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders
Astellas Pharma and Cullgen have announced a research collaboration and exclusive option agreement to discover […]
Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program
Auxilius Pharma has consolidated its funding of $1 Million for developing its lead asset, AUX-001, […]